With seasonal occurrence of influenza, the healthcare authorities and pharmaceutical manufacturers are focusing on development of novel medications and spreading awareness about the disease. Among the types of influenza viruses, type-A and type-B are considered to be responsible for the spread of epidemic and pandemic. Influenza is characterized by fever, muscle ache, fatigue, cold, cough, sore throat and may lead to chronic respiratory diseases. The individuals with previous medical history, pregnant women, and aged people are highly susceptible to the influenza viruses. The Rapid Influenza Diagnostic Test (RIDTs) is antigen detection assay-based detection method for detecting type-A and type-B influenza viruses. The RIDTs are widely used and are evolving rapidly with advancement in technology. Leading players in the market are focusing on development of novel therapeutics for treatment influenza, which is anticipated to bolster the growth of the global influenza medication market during the forecast period.
North America contributed a dominating share to the global influenza medication market in 2019 and is expected to witness prominent growth during the forecast period. Increasing number of influenza tests, prevalence of influenza, increasing investment in novel drug discovery, government initiative to promote vaccination against influenza, and favorable insurance reimbursement policies are the major contributors towards the North America influenza medication market. Asia Pacific is anticipated to witness significant growth during the forecast period owing to strong prevalence of influenza in China, India, and Southeast Asian countries. Additionally, the pharmaceutical manufacturers in the region are working in close conjunction with the healthcare authorities to spread awareness about influenza along with expansion of manufacturing facilities to cater the rising demand. This is anticipated to fuel the growth of Asia Pacific influenza medication market in coming years.
The report titled “Influenza Medication Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032” wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the global influenza medication market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market. For instance, GlaxoSmithKline plc reported revenues of USD 41,615.1 million in 2019 and the product segment analysis of the company indicates that Pharmaceuticals business segment of the company dominated revenue in 2019.
The global influenza medication market is segmented based on product type, sales channel, and geography. Based on product type, the global influenza medication market is segmented into Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and others. Based on sales channel, the global influenza medication market is segmented into hospitals, clinics, pharmacies, and others. Based on geography, the global Influenza Medication market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America.
The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment, and would identify the segment of the company focusing on influenza medications and vaccines. Further, market share of prominent companies in the global Influenza Medication market would also be estimated. For instance, GlaxoSmithKline plc operates through three business segments namely Pharmaceuticals, Vaccines and Consumer Healthcare. The Influenza Medications are delivered under Vaccines business segment of the company with revenue contribution of US$ 8,826.3 million in 2019.
The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, SWOT analysis, and research and development focus of all the influenza medication producers. The global influenza medication market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the influenza medication business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the global influenza medication market.
Major players active in the global influenza medication market include Alvogen, Amneal Pharmaceuticals LLC, BIOCRYST PHARMACEUTICALS, INC., Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline plc, Lupin Limited, Mylan, Inc., Natco Pharma, Novartis AG, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals, Inc.
Global Influenza Medication Market Key Segments:
By Distribution Channel
The Influenza Medication analysis market has been assessed for the years 2023 to 2032.
Based on Product, the Influenza Medication market is segmented into Zanamivir, Oseltamivir ,Peramivir, Amantadine ,Rimantadine ,Inosine and Others.
Some key players operating in the Influenza Medication market include Alvogen, Amneal Pharmaceuticals LLC, BIOCRYST PHARMACEUTICALS, INC., Daiichi Sankyo Company, F. Hoffmann-La Roche Ltd., Genentech, Inc., GlaxoSmithKline plc..
Copyright © 2023 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved